Is Cytomegalovirus Surveillance Necessary for Patients With Low Reactivation Risk in an Autologous Hematopoietic Cell Transplantation Setting?

Kaya, A.; Tekgunduz, E.; Akpinar, S.; Batgi, H.; Bekdemir, FİLİZ; Kayikci, O.; Namdaroglu, S.; Ulu, B.; Dal, M.; Cakar, M.; Korkmaz, S.; Altuntas, F.

doi:10.1016/j.transproceed.2017.05.007

Is Cytomegalovirus Surveillance Necessary for Patients With Low Reactivation Risk in an Autologous Hematopoietic Cell Transplantation Setting?

Kaya A. H., Tekgunduz E., Akpinar S., Batgi H., Bekdemir F., Kayikci O., ...More

TRANSPLANTATION PROCEEDINGS, vol.49, no.8, pp.1911-1915, 2017 (SCI-Expanded, Scopus)

Publication Type: Article / Article
Volume: 49 Issue: 8
Publication Date: 2017
Doi Number: 10.1016/j.transproceed.2017.05.007
Journal Name: TRANSPLANTATION PROCEEDINGS
Journal Indexes: Science Citation Index Expanded (SCI-EXPANDED), Scopus
Page Numbers: pp.1911-1915
Eskisehir Osmangazi University Affiliated: Yes

Abstract

Background. In an autologous hematopoietic cell transplantation (AHCT) setting, routine cytomegalovirus (CMV) surveillance is not indicated except in high-risk situations. On the other hand, some studies reported increased CMV reactivation in AHCT setting as a result of incorporation of novel agents into treatment algorithms, such as bortezomib and rituximab. We retrospectively analyzed CMV reactivation and infection rates in patients with no high-risk features, who were treated with AHCT.